It's should be there..A month ago there was an article which pharma will go higher first, ACAD or CLDX?It appears that CLDX is pulling up faster. Maybe ACAD needs a push with a good clinical update soon to go up higher.
By then we should know the design of the adp trial perhaps also schizo. More importantly what will happen with pimavanserin in Europe and Japan. I guess they will announce a partnership with one of the big ones.
I know Uli "said" they were "on the path" to ramping up operations to support the launch, but I just can't believe this is something they do on their own--can u? Its no small feat to get the 70-80 sales rep's Uli mentioned plus a whole host of other "things" this has to end up as a JV or buyout???